Atlas Trials

STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors

Clinical trial NCT00088101 · COMPLETED

Trial details

NCT number
NCT00088101
Sponsor
Synta Pharmaceuticals Corp.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hematological MalignanciesLeukemiaLymphomaMetastatic or Unresectable Solid Tumors
Start date
2004-02-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.